12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Stem Cell Therapeutics, Trillium Therapeutics deal

The companies will merge in a cash and stock deal that values Trillium at C$2.9 million ($2.9 million). Trillium shareholders will receive C$1.2 million ($1.2 million) in cash and C$1.7 million ($1.7 million) in shares of Stem Cell Therapeutics. Stem Cell Therapeutics said Trillium's principal shareholders have indicated they will support the deal, which is expected to close this half. Stem Cell Therapeutics said the...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >